Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Carpenter

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Treatment Options in Oncology|December 17, 2013
How do I recommend extended adjuvant hormonal therapy?Amitkumar Mehta, John T Carpenter
JAMA|August 20, 2009
Estradiol in breast cancer treatment: reviving the pastPamela N Munster, John T Carpenter
Breast Cancer Research and Treatment|September 18, 2017
Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008Roisin M Connolly, Mary Jo Fackler, Zhe Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson, Donald A Berry, George D Demetri, et al.
Clinical Breast Cancer|August 14, 2010
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancerAndres Forero-Torres, Mansoor N Saleh, Janice A Galleshaw, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Treatment Options in Oncology|December 17, 2013
How do I recommend extended adjuvant hormonal therapy?Amitkumar Mehta, John T Carpenter
JAMA|August 20, 2009
Estradiol in breast cancer treatment: reviving the pastPamela N Munster, John T Carpenter
Breast Cancer Research and Treatment|September 18, 2017
Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008Roisin M Connolly, Mary Jo Fackler, Zhe Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson, Donald A Berry, George D Demetri, et al.
Clinical Breast Cancer|August 14, 2010
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancerAndres Forero-Torres, Mansoor N Saleh, Janice A Galleshaw, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Pageof 1